Screening for dyslipidemia in younger adults: A systematic review for the U.S. Preventive services task force

Annals of Internal Medicine

Volumn 165, Issue 8, 2016, Pages 560-564

  Chou, Roger ^a   Dana, Tracy ^a   Blazina, Ian ^a   Daeges, Monica ^b   Bougatsos, Christina ^a   Jeanne, Thomas L ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b DUKE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL OUTCOME; COCHRANE LIBRARY; COHORT ANALYSIS; DIAGNOSTIC VALUE; DRUG EFFICACY; DYSLIPIDEMIA; FOLLOW UP; HUMAN; LIFESTYLE; LIPID ANALYSIS; MEDLINE; PREVENTIVE HEALTH SERVICE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UNITED STATES; ADULT; ADVERSE EFFECTS; ASYMPTOMATIC DISEASES; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DYSLIPIDEMIAS; MASS SCREENING; MORTALITY; RISK FACTOR; YOUNG ADULT;

ADULT; ASYMPTOMATIC DISEASES; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DYSLIPIDEMIAS; HUMANS; MASS SCREENING; RISK FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84992630856     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-0946     Document Type: Review

References (28)

1. Tó th PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol. 2012;6:325-30. [PMID: 22836069] Doi: 10.1016/j.jacl.2012.05.002
2. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008;156:112-9. [PMID: 18585505] Doi: 10.1016/j.ahj.2008.03.005
3. Centers for Disease Control and Prevention (CDC). Prevalence of coronary heart disease-United States, 2006-2010. MMWR Morb Mortal Wkly Rep. 2011;60:1377-81. [PMID: 21993341]
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-245. [PMID: 23239837] Doi: 10.1161/CIR.0b013e31828124ad
5. Minino AM. Death in the United States, 2011. NCHS Data Brief no 115. Hyattsville, MD: National Center for Health Statistics; 2013.
6. U.S. Preventive Services Task Force. Lipid disorders in adults (cholesterol, dyslipidemia): screening. 2008. Accessed at www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummary Final/lipid-disorders-in-adults-cholesterol-dyslipidemia-screening on 8 June 2016.
7. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2935-59. [PMID: 24239921] Doi: 10.1016/j.jacc.2013.11.005
8. National Diabetes Education Initiative. Diabetes management guidelines: American Diabetes Association (ADA) 2016 guidelines. 2013. Accessed at www.ndei.org/ADA-diabetes-management-guidelines-diagnosis-A1C-testing.aspx on 8 June 2016.
9. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al; European Association for Cardiovascular Prevention & Rehabilitation. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818. [PMID: 21712404] Doi: 10.1093/eurheartj/ehr158
10. Genest J, Frohlich J, Fodor G, McPherson R; Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ. 2003;169: 921-4. [PMID: 14581310]
11. Helfand M, Carson S. Screening for Lipid Disorders in Adults: Selective Update of 2001 U.S. Preventive Services Task Force Review. AHRQ publication no. 08-05114-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2008. Accessed at www.uspreventiveservicestaskforce.org/Page/Document/Update SummaryFinal/lipid-disorders-in-adults-cholesterol-dyslipidemia-screening?ds=1&s=dyslipidemia on June 8, 2016.
12. Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD, Lohr KN. Screening and treating adults for lipid disorders. Am J Prev Med. 2001;20:77-89. [PMID: 11306236]
13. Pignone MP, Phillips CJ, Lannon CM, Mulrow CD, Teutsch SM, Lohr KN, et al. Screening for Lipid Disorders. AHRQ publication no. 01-S004. Rockville, MD: Agency for Healthcare Research and Quality; 2001. Accessed at www.ahrq.gov/downloads/pub/prevent/pdfser/lipidser.pdf on June 8, 2016.
14. Chou R, Dana T, Blazina I, Daeges M, Bougatsos C, Jeanne T. Statins for Prevention of Cardiovascular Disease in Adults: Systematic Review for the U.S. Preventive Services Task Force. Evidence Synthesis no. 139. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
15. Lozano P, Henrikson NB, Morrison CC, Dunn J, Nguyen M, Blasi P, et al. Draft evidence review: lipid screening in childhood for detection of multifactorial dyslipidemia: a systematic review for the U.S. Preventive Services Task Force. 2015. Accessed at www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review-screening-for-multifactorial-dyslipide/lipid-disorders-in-children-screening1 on 8 June 2016.
16. U.S. Preventive Services Task Force. Procedure manual. 2016. Accessed at www.uspreventiveservicestaskforce.org/Page/Name/methods-and-processes on 8 June 2016.
17. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35. [PMID: 11306229]
18. Chou R, Dana T, Blazina I, Daeges M, Bougatsos C, Jeanne T. Screening for Dyslipidemia in Younger Adults: A Systematic Review to Update the 2008 U.S. Preventive Services Task Force Recommendation. Evidence Synthesis no. 138. AHRQ publication no. 14-05206-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
19. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809-16. [PMID: 15492322]
20. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306-14. [PMID: 20048204] Doi: 10.1161/CIRCULATIONAHA.109.900027
21. Beishuizen ED, van de Ree MA, Jukema JW, Tamsma JT, van der Vijver JC, Meinders AE, et al. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care. 2004;27:2887-92. [PMID: 15562202]
22. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117:823-9. [PMID: 15589485]
23. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423. [PMID: 19001495] Doi: 10.1136/bmj.a2423
24. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78. [PMID: 16214597]
25. Kreger BE, Odell PM, D'Agostino RB, Wilson PF. Long-term intraindividual cholesterol variability: natural course and adverse impact on morbidity and mortality-the Framingham Study. Am Heart J. 1994;127:1607-14. [PMID: 8197990]
26. Bakx JC, van den Hoogen HJ, Deurenberg P, van Doremalen J, van den Bosch WJ. Changes in serum total cholesterol levels over 18 years in a cohort of men and women: The Nijmegen Cohort Study. Prev Med. 2000;30:138-45. [PMID: 10656841]
27. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet. 1969;2:1380-2. [PMID: 4188273]
28. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;49:476-88. [PMID: 4813182]